UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 1815, ~~2012~~ 2013

HUMAN PHEROMONE SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

CALIFORNIA	0-23544	94-3107202
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

84 W. SANTA CLARA STREET, SUITE 720, SAN JOSE, CALIFORNIA	95113
(Address of principal executive offices)	(Zip code)

84 W. SANTA CLARA STREET, SUITE 720, SAN JOSE, CALIFORNIA 95113

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (408) 938-3030

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~|_|~~¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~|_|~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~|_|~~¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~|_|~~¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 35.02(b). ~~Unregistered~~Departure ~~Sales~~of Directors or Certain Officers; Election of ~~Equity~~Directors; ~~Securities~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 1815, ~~2012~~2013 ~~Human~~Mr. ~~Pheromone~~Robert ~~Sciences,~~Marx ~~Inc.~~informed the ~~(‘Company”)~~Board ~~issued~~of toDirectors ~~CrowdGather~~of Human Pheromone Sciences, Inc. (the “~~CrowdGather~~Company”) ~~714,286 shares~~ of ~~restricted~~his ~~common~~resignation ~~stock~~effective ~~pursuant~~immediately tofor personal ~~Asset~~reasons. ~~Purchase~~Mr. Marx, ~~and~~who ~~License~~has ~~Agreement~~served ~~between~~as ~~the~~an ~~Company~~independent ~~CrowdGather~~director ~~dated~~of ~~May~~the ~~16,~~Company ~~2011~~since ~~(the~~October ~~“Agreement”)~~1994.

~~Pursuant~~- to2 the Agreement, upon receipt and acceptance of the EROX Product by CrowdGather, the $50,000 advance payment received by the Company was converted into restricted common stock of the Company at $0.07 per share, the closing price of the Company’s common stock on January 17, 2012.-

The issuance of the Company’s common stock to CrowdGather pursuant to the Agreement was not be registered under the Securities Act of 1933, as amended. Such shares were issued in reliance upon the exemption for transactions by an issuer not involving a public offering under Section 4(2) of the Securities Act.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HUMAN PHEROMONE SCIENCES, INC.
Date: January 19, 2012	By:	/s/ William P. Horgan
Date: January 16, 2013	By:	/s/ William P. Horgan
		William P. Horgan, Chief Executive Officer

- 2 3 -

Filing Compare · HUMAN PHEROMONE SCIENCES INC